F-FDOPA PET/CT Combined with MRI for Gross Tumor Volume Delineation in Patients with Skull Base Paraganglioma.

Fiche publication

Date publication

janvier 2019

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Pr NOEL Georges , Pr IMPERIALE Alessio , Dr LE FEVRE Clara , Dr BUND Caroline

Tous les auteurs :
Helali M, Moreau M, Le Fèvre C, Heimburger C, Bund C, Goichot B, Veillon F, Hubelé F, Charpiot A, Noel G, Imperiale A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30626096

Résumé

In this simulation study, we assessed differences in gross tumor volume (GTV) in a series of skull base paragangliomas (SBPGLs) using magnetic resonance imaging (MRI), F-dihydroxyphenylalanine (F-FDOPA) combined positron emission tomography/computed tomography (PET/CT), and F-FDOPA PET/MRI images obtained by rigid alignment of PET and MRI. GTV was delineated in 16 patients with SBPGLs on MRI (GTV), F-FDOPA PET/CT (GTV), and combined PET/MRI (GTV). GTV was the union of GTV and GTV after visual adjustment. Three observers delineated GTV and GTV independently. Excellent interobserver reproducibility was found for both GTV and GTV. GTV and GTV were not significantly different. However, there was some spatial difference between the locations of GTV, GTV, and GTV. The Dice similarity coefficient median value was 0.4 between PET/CT and MRI, and 0.8 between MRI and PET/MRI. The combined use of PET/MRI produced a larger GTV than MRI alone. Nevertheless, both the target-delivered dose and organs-at-risk conservancy were respected when treatment was planned on the PET/MRI-matched data set. Future integration of F-FDOPA PET/CT into clinical practice will be necessary to evaluate the influence of this diagnostic modality on SBPGL therapeutic management. If the clinical utility of F-FDOPA PET/CT and/or PET/MRI is confirmed, GTV should be considered for tailored radiotherapy planning in patients with SBPGL.